
The Food and Drug Administration (FDA) has granted accelerated approval to Tecentriq (atezolizumab; Genentech) in combination with Abraxane (paclitaxel [bound to albumin (human), nab-paclitaxel]; Celgene) for the treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) in people whose tumors express programmed death-ligand 1 (PD-L1), as determined by an FDA-approved test. The approval, which is contingent upon verification and description of clinical benefit in confirmatory trials, was based on data from the phase 3 IMpassion130 study. Patients (N=902) with unresectable locally advanced or metastatic TNBC who had not received prior systemic therapy for metastatic breast cancer were randomized to receive Tecentriq + nab-paclitaxel or placebo + nab-paclitaxel. The co-primary endpoints were progression-free survival (PFS) and overall survival.
Source: Cancer Therapy Advisor







